金吾财讯 | Biora Therapeutics(BIOR)盘前涨超12%，截至发稿，报0.79美元。消息面上，Biora Therapeutics最近公布了其BT-600一期试验的补充数据，该药物是一种利用Navi Cap设备将药物靶向输送至结肠的溃疡性结肠炎治疗药物。
研究结果表明，该药物成功实现了全身吸收，与传统口服治疗相比，全身暴露量显着减少，并在整个结肠中有效分布。试验突出了Navi Cap设备的精确释放和高耐受性，没有出现严重不良事件或结肠毒性迹象。这一进展标志着针对性溃疡性结肠炎治疗的潜在突破，该治疗具有持续的药物作用和最小的副作用。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.